Amferia signs major contract in Animal Health with Grovet BV and Expands into the Benelux markets
Mölndal, Sweden — February 5, 2026 — An innovative new wound care technology will now allow veterinarians in the Benelux countries to protect wounds from bacterial infections and help heal animal wounds faster. Amferia, a Swedish medtech company developing next-generation antimicrobial wound-care solutions, announced a distribution partnership with Grovet BV —a major player serving the animal health market in European countries including Netherlands, Belgium, and Luxemburg.
The joint efforts will aim to make products available as soon as the spring of 2026.
The partnership with Grovet will bring a groundbreaking treatment to animal patients in the Benelux region. Extensive research across Europe demonstrates that Amferia’s dressing helps heal wounds significantly faster than currently available dressings.
But Amferia’s greatest promise might lie in its proven ability to counter the rising threat of antibiotic-resistant bacteria. Because Amferia kills bacteria by drawing them close and physically puncturing their cell membranes, even bacterial strains that have developed a resistance to medical antibiotics cannot effectively resist this interaction.
This distribution agreement follows a milestone year in which Amferia introduced Europe’s first veterinary wound dressing using antimicrobial peptides, launched in collaboration with leading animal-health partners, and advanced efforts to achieve regulatory approval in the U.S. for human wound care.
Fueling Growth Across Veterinary Medicine
According to Amferia Sales and Marketing Director and co-founder Saba Atefyekta, the new partnership will help Grovet advance its animal wound care offerings, as well as expand Amferia’s animal-health footprint in Europe, where its products are already available in Scandinavia, Germany, Spain and Switzerland.
“Grovet’s market leadership in animal health will spearhead Amferia’s vision of addressing antibiotic-resistant wound infections. This partnership brings our innovation together with a leading partner in a market in need of new solutions. Veterinarians across Europe have shown strong interest in our innovation. They immediately recognize the potential for our new antimicrobial material for wound and infection management,” Atefyekta said.
“We are very excited about Amferia’s innovative technology for wound care in animals and we clearly see its potential to contribute to the battle against antibiotic-resistance. We are looking forward to launch AMP Wound Dressing in the Benelux very soon,” said Chris Dujardin, Head of Business Development at Grovet.
The Race to Solve Global Antimicrobial Resistance
Antimicrobial resistance (AMR) is accelerating at a pace that threatens to become one of the leading causes of human mortality worldwide in coming decades. At least five million people are currently affected by infections caused by antibiotic resistance. In countries with a high incidence of resistant bacteria, such as China and large parts of Africa, a small wound can cause life-threatening infection that can’t be treated with traditional antibiotics.
Antimicrobial peptides are known for their ability to kill bacteria due to their positive electrostatic charge, which attracts the negatively charged infectious bacteria. This allows peptides to puncture bacterial membranes and destroy the cells. However, their fragility in biological environments has been a major challenge to developing peptides as a viable treatment—naturally occurring enzymes in the body can destroy them within seconds.
Amferia's wound dressing for animals - encasing the peptides in a solid protective gel. This design shields the vulnerable facets of peptides while allowing their bacteria-killing structures to remain exposed
Amferia’s breakthrough is the development of a hydrogel platform, encasing the peptides in a solid protective gel. This design shields the vulnerable facets of peptides while allowing their bacteria-killing structures to remain exposed—and lethal to even antibiotic-resistant bacteria. Amferia's antimicrobial hydrogel kills bacteria without harming surrounding body tissue.
“The hydrogel technology we’ve developed enables the safe and stable use of antimicrobial peptides—one of nature’s most powerful defenses—while preventing the enzyme degradation that has historically limited their use,” Atefyekta said.
Research shows that combining Amferia’s hydrogel with antibiotics can dramatically amplify their bactericidal effect—up to 64 times stronger—demonstrating its potential to reshape infection management.
Looking Ahead
Amferia continues to expand its product pipeline, invest in research, and collaborate with global partners to redefine how infections are prevented and managed. By stabilizing one of nature’s most effective bacterial defenses, the company offers a transformative platform with the potential to strengthen antibiotic treatments and improve outcomes across healthcare.
Learn more about Amferia
https://www.amferia.com/
https://news.cision.com/amferia-ab/r/new-study-finds-innovative-peptide-hydrogel-restores-the-effectiveness-of-antibiotics-against-drug-r,c4067581
https://news.cision.com/amferia-ab/r/first-product-utilizing-amferia-antimicrobial-technology-launched-in-europe-for-animal-wound-care,c4058570
https://news.cision.com/amferia-ab/r/amferia-wins-red-dot-award-for-innovative-design-addressing-bacterial-infections-and-antibiotic-resi,c4063979
Contact
Saba Atefyekta
Sales Director & Co-Founder, Amferia
sabaa@amferia.com
